| __timestamp | BeiGene, Ltd. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 2917513 |
| Thursday, January 1, 2015 | 7311000 | 7878291 |
| Friday, January 1, 2016 | 20097000 | 8366794 |
| Sunday, January 1, 2017 | 62602000 | 6610381 |
| Monday, January 1, 2018 | 195385000 | 6556000 |
| Tuesday, January 1, 2019 | 388249000 | 6930000 |
| Wednesday, January 1, 2020 | 600176000 | 8758000 |
| Friday, January 1, 2021 | 990123000 | 10806000 |
| Saturday, January 1, 2022 | 1277852000 | 9844000 |
| Sunday, January 1, 2023 | 1504501000 | 13481000 |
Data in motion
In the dynamic world of biotechnology, understanding financial health is crucial. BeiGene, Ltd. and Soleno Therapeutics, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. BeiGene, a global biotechnology company, has seen its SG&A expenses skyrocket by over 21,000% from 2014 to 2023, reflecting its aggressive expansion and operational scaling. In contrast, Soleno Therapeutics, focused on rare diseases, has maintained a more modest increase of approximately 360% over the same period. This disparity highlights the differing strategic approaches: BeiGene's rapid growth and market penetration versus Soleno's steady, focused development. As the biotech sector continues to evolve, these financial insights provide a window into the strategic priorities and operational efficiencies of these two companies.
Operational Costs Compared: SG&A Analysis of GSK plc and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for Biogen Inc. and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Insmed Incorporated
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Comparing SG&A Expenses: Viatris Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs Soleno Therapeutics, Inc. Trends and Insights